NCODA Logo

This document will provide awareness of the PI3K inhibitor, inavolisib, for patients receiving treatment for hormone receptor (HR)-positive, HER2-negative, advanced/metastatic breast cancer and will discuss counseling, monitoring parameters, and patient management strategies to optimize adherence and improve patient outcomes.